MedTech Innovator

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

APrevent Medical Inc. is a medical device company based in Taipei, Taiwan, with an additional office in Austria. Founded in 2014, the company specializes in developing therapeutic devices aimed at enhancing the quality of life for patients affected by speech disorders. APrevent focuses on creating long-term implant systems and a speech conversion platform, along with other innovative medical equipment. Their offerings include minimally invasive ENT implants and Software-as-a-Service technologies designed to assist in the treatment of voice and communication disorders, enabling patients to improve their speech capabilities effectively.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices, particularly for infectious diseases such as influenza. The company manufactures microchip devices that allow users to achieve rapid and accurate diagnoses, which are essential for medical professionals in practical healthcare settings. By providing timely information, Nanotis aims to enhance the efficiency of healthcare delivery and assist individuals facing health challenges.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

FibriCheck is a medically certified mobile application designed for the screening and monitoring of irregular heart rhythms, particularly atrial fibrillation. As a software-only solution, it allows users to measure their cardiac rhythm simply by placing their finger on their smartphone camera, making it accessible anytime and anywhere. The application automatically shares gathered information with medical professionals, facilitating quicker diagnoses and enabling tailored treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, leveraging everyday smartphones and wearables to accurately detect and monitor heart rhythm issues. This innovative approach aims to enhance cardiovascular care by providing users with effective tools to manage their heart health, ultimately improving efficiency and reducing costs associated with cardiovascular treatments.

Ortho-tag specializes in developing innovative technologies that facilitate wireless communication between digital health applications and implanted medical devices. Their in-vivo platform enables real-time data exchange and in-body communication through a proprietary method known as transcutaneous volume conduction. This technology enhances the functionality of smart medical implants by allowing for efficient powering, data storage, and nano diagnostic capabilities. By bridging the gap between digital health technologies and the human body, Ortho-tag aims to improve the integration and performance of medical devices, thereby enhancing patient care and monitoring.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

Qritive is a developer of an AI-powered diagnostic platform that assists medical professionals in analyzing microscopy images and patient data. The platform leverages artificial intelligence and natural language processing to streamline the analysis process, enhancing the efficiency of cancer diagnoses. By providing modern automated tools, Qritive aims to reduce the time and costs associated with cancer diagnosis, ultimately improving healthcare outcomes for patients. The company's innovative approach addresses the challenges faced by doctors in interpreting complex medical information, facilitating quicker and more accurate diagnoses.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

INIA Biosciences focuses on creating non-invasive medical devices that leverage sound wave technology to manage chronic inflammatory diseases. The company's innovative system combines biomarker monitoring with an ultrasound stimulator, aimed at reducing inflammation associated with transplant rejection and decreasing reliance on immunosuppressant medications. This home-administered, closed-loop monitoring system provides physicians with advanced diagnostic capabilities to improve the treatment and prevention of organ failure, ultimately enhancing patient care in chronic disease management.

Niramai Health Analytix Private Limited is a Bengaluru-based company founded in 2016 that specializes in cancer screening solutions. Its primary product, Thermalytix, is a software that utilizes machine intelligence to analyze thermography images, enabling early detection of breast cancer. This innovative approach allows for the identification of tumors significantly smaller than those detectable by traditional methods, making it a critical tool for improving survival rates. Niramai’s offerings include a compact screening device for specialty hospitals, a handheld device for independent medical practitioners with real-time cloud-based diagnostics, and a portable solution suitable for large-scale screenings. The technology is designed to be cost-effective, non-invasive, painless, and free of radiation, allowing women across all age groups to undergo frequent screenings with minimal human supervision and side effects.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

IFPx is a company focused on developing innovative patient monitoring technology aimed at improving the management of chronic illnesses, specifically heart failure. Its platform features advanced sensors that measure interstitial fluid pressure, allowing healthcare professionals to directly analyze fluid buildup in patients. This technology aims to enhance the monitoring and treatment of heart conditions, ultimately transforming patient care and outcomes in this critical area of healthcare.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostics aimed at identifying high-risk markers for stomach cancer. The company utilizes next-generation technology and precision immunology to create tests that exceed the capabilities of current antibody screenings, offering enhanced precision and more comprehensive disease information. By improving diagnostic accuracy, Biotome seeks to equip medical professionals with the tools necessary to provide better treatment options for patients, ultimately benefiting healthcare outcomes globally.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.

Senseye, Inc. is a company based in Los Angeles, California, focused on developing smart contact lenses that non-invasively gather data from users. Founded in 2015, the company aims to infer human emotions, thoughts, and health states to support various applications in market research, disease diagnosis, and early detection of conditions such as strokes and heart attacks. By utilizing innovative measurements of ocular physiology, Senseye quantifies cognitive abilities, health metrics, and psychological well-being, including vital signs and cognitive load. The platform is designed to enhance clinicians' ability to provide personalized care, allowing them to establish baselines and monitor patient outcomes effectively. As the technology advances, Senseye intends to place greater emphasis on emotional responses and mental health diagnostics, offering new insights into cognitive and health parameters through standard camera equipment.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.

Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

3EO Health is focused on creating a society where individuals can take charge of their health, benefiting themselves, their families, and their communities. The company develops innovative molecular point-of-care platforms that utilize advanced technology to significantly reduce costs while enhancing access to impactful diagnostic tools. By offering 3TR technology, 3EO Health ensures that both physicians and consumers have equitable access to affordable and user-friendly health solutions. This approach aims to extend healthcare beyond traditional settings into communities, workplaces, and homes, empowering people to thrive and optimize their health effectively.

CORIT Medical LLC is a medical device company based in McLean, VA, specializing in a Class I single-use surgical device designed to enhance breathing. Their patented device is specifically aimed at improving the established Ear, Nose & Throat (ENT) procedure known as inferior turbinate reduction. With over 1 million procedures performed annually in the U.S. and more than 50 million individuals suffering from obstructed breathing, CORIT's hand-powered device offers an efficient solution, requiring no expensive setup or equipment. The device not only allows ENT specialists to perform the procedure quickly in their offices, but it also yields long-lasting results compared to existing technologies, which may revert to pre-treatment obstruction levels within six months. This combination of efficiency and effectiveness has generated significant interest among ENTs, who are eager to adopt the device due to its potential for higher reimbursement rates and improved patient outcomes.

4th Dimension EMR develops electronic health record (EHR) software aimed at assisting healthcare practitioners in managing patient information and documentation. The company offers a cloud-based platform that enhances practice management by streamlining scheduling and ensuring that medical records are accessible anytime and anywhere. This software is designed to improve workflow efficiency for medical practices, allowing practitioners to focus more on patient care while effectively maintaining comprehensive records.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. The company specializes in developing advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and materials. Its primary product is a multi-modal coherent Raman scattering microscope, which is designed for both research and high-value medical applications. This innovative imaging system facilitates intraoperative histology by providing high-resolution images that allow researchers to examine tissue specimens from multiple surgical sites. Invenio Imaging's technology is underpinned by research from Prof. Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

Prana Thoracic, Inc. is a Houston-based medical device startup focused on addressing the challenges of early intervention in lung cancer, which remains a leading cause of cancer-related deaths in the United States. The company aims to enhance screening and diagnosis by developing advanced surgical tools that facilitate the capture and analysis of small, suspicious lung nodules. Their innovative device employs a tissue-sparing electrosurgical technique that utilizes bipolar radiofrequency energy, allowing for simultaneous cutting and sealing. This approach minimizes the risk of complications associated with traditional methods, thereby improving the prospects for early detection and treatment. By providing physicians with more effective tools, Prana Thoracic seeks to revolutionize the management of lung cancer, ensuring that patients receive timely interventions and improving overall survival rates.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions earlier than traditional methods.

CARI Health is a digital health company based in San Diego, California, that specializes in the development of remote medication monitors. Founded in 2015 and incorporated in 2021, the company creates wireless sensors that patients wear on their skin. These sensors continuously transmit real-time data about medication levels to the cloud, allowing clinicians to safely prescribe, dose, and monitor adherence to critical medications. By providing this innovative solution, CARI Health aims to enhance patient care and improve health outcomes through better medication management.

LiveMetric is a medical device company focused on developing non-invasive sensing and deep data analytics solutions aimed at transforming the management of hypertension and cardiovascular diseases. The company has created a wearable, cuff-free device for blood pressure monitoring, which has received FDA clearance and is validated for accuracy against traditional arterial line measurements. This device offers continuous monitoring of vital signs, enabling healthcare providers to deliver AI-augmented care and treatment management. LiveMetric aims to empower patients, payors, and healthcare professionals with accurate, personalized data, facilitating better decision-making and improving the overall quality of care for individuals suffering from chronic cardiovascular conditions. By providing detailed daily activity mapping and real-time feedback, the company seeks to enhance the lives of millions worldwide affected by these health issues.

Garwood Medical Devices, LLC is a Buffalo, New York-based company that specializes in developing and manufacturing medical devices focused on infection management, particularly related to prosthetic implants and wound healing. The company's flagship product, BioPrax, is a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. This innovative approach allows medical practitioners to effectively treat implant infections without the need for follow-up surgeries, thereby enabling patients to retain their implants. Founded in 2014 and initially known as Enermed, LLC, the company adopted its current name in December 2015, reflecting its commitment to advancing medical technology in infection control.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients at home. The device employs a closed-loop approach and machine learning algorithms to deliver personalized peripheral neuromodulation therapy. This innovative technology mediates a cardiovascular antiarrhythmic response, helping users to alleviate the burden of atrial fibrillation and address precursors such as premature atrial contractions. As a result, CardiaCare’s device offers users the potential for rapid clinical and symptomatic relief.

Tricog Health specializes in developing advanced cardiac diagnostic tools aimed at addressing cardiovascular conditions with precision and timeliness. Utilizing medical-grade artificial intelligence, Tricog's solutions facilitate real-time reporting and analysis of electrocardiography results, enabling healthcare providers to identify cardiac issues quickly and accurately. The company focuses on bridging gaps in cardiac care infrastructure, expertise, and efficiency, ensuring that patients receive prompt diagnoses and timely interventions. Tricog is dedicated to enhancing cardiac care accessibility by providing virtual diagnostic tools and services, thereby supporting healthcare professionals in delivering reliable and consistent patient care.

Augment Health focuses on enhancing the management of bladder dysfunction, particularly for the 7 million patients affected by neurological diseases or injuries. The company is developing a noninvasive bladder monitor along with an AI algorithm that allows for home diagnostics, addressing the high rate of inconclusive results seen in clinical settings. By shifting bladder health monitoring out of the clinic, Augment Health's technology aims to prevent complications such as bladder muscle atrophy by notifying patients or caregivers when the catheter is full, thus promoting better bladder health management. This innovation targets a significant market valued at $12.3 billion, providing a practical solution to improve the quality of life for individuals facing bladder dysfunction.

SafeBeat Rx specializes in advanced electrocardiogram technology that enhances cardiac monitoring by allowing patients to manage their care remotely. The company's software facilitates remote patient monitoring, continuous telemetry, and event monitoring, thus eliminating the need for prolonged hospital stays. SafeBeat Rx's solutions are particularly beneficial for arrhythmia patients, as they enable safe initiation of medications and ongoing management from home. Powered by automated artificial intelligence, their technology also supports the monitoring of cardiac implantable electronic devices, making cardiac care more accessible and efficient for patients.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

ConKay Medical Systems is an early-stage medical device company focused on developing innovative solutions to address valvular regurgitation in patients suffering from progressive heart failure. The company's technology is centered around annular repair, which targets the primary cause of functional regurgitation while preserving the integrity of healthy leaflets. This approach aims to enhance the effectiveness of cardiovascular care, providing healthcare professionals with advanced tools to better manage this condition.

DermaSensor, Inc. is a Miami-based company that develops a handheld device designed to evaluate skin lesions for cancer using artificial intelligence and spectroscopy. Founded in 2009, the company's flagship product enables both physicians and consumers to conduct skin checks conveniently in clinical settings and at home. The device employs elastic scattering spectroscopy and machine learning algorithms to rapidly assess skin lesions, helping to identify potential cancerous cells. By providing an affordable and efficient tool for early detection, DermaSensor aims to improve access to skin cancer evaluations, addressing the significant number of Americans who have never undergone such checks. The technology not only facilitates immediate assessments but also alerts users when cancerous cells are detected, streamlining the process of skin cancer diagnostics.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.

InVera Medical is a developer of innovative medical devices aimed at treating varicose veins and venous ulcers. The company focuses on creating less invasive, pain-free treatment options that leverage the body's natural biological responses. Their proprietary technology provides a minimally invasive endovenous treatment that enhances patient safety and efficacy, addressing a significant gap in the market where only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. With an estimated 3 million patients with venous ulcers currently underserved and reliant on ineffective compression bandaging, InVera Medical offers a solution that not only improves treatment outcomes but also seeks to reduce the substantial annual costs incurred by insurers. Their approach is positioned to disrupt conventional treatment practices and expand the indications for superficial venous ablation, ultimately enhancing access to effective care for a broader range of patients.

CloudCath is a company that specializes in developing a remote monitoring platform for peritoneal dialysis patients. Their innovative system utilizes sensor-enabled technology to provide continuous monitoring, allowing for early detection of complications associated with catheter-based treatments. By leveraging Internet of Things (IoT) capabilities, CloudCath's platform enables healthcare providers to remotely oversee patients during their home treatment, significantly reducing the frequency of in-person visits. This approach not only enhances patient safety but also improves the overall management of care for individuals undergoing peritoneal dialysis, ultimately promoting better health outcomes.

Respirix, Inc. is a United States-based company that specializes in developing advanced sensors for monitoring breath exhalation and cardiogenic oscillations. The company combines digital health software and hardware to deliver proprietary insights into the pulmonary vasculature in a non-invasive manner. Respirix's product pipeline focuses on both at-home monitoring and critical care applications, particularly targeting conditions such as heart failure and hemodynamics. Through its innovative technologies, Respirix aims to enhance patient care by providing accurate and real-time health monitoring solutions.

HD Medical specializes in innovative cardiovascular diagnostic solutions, focusing on the development of a visual stethoscope that integrates electrocardiogram (ECG) technology. This device enables healthcare professionals to visualize heart sounds and cardiac waveforms in real time at the point of care. By allowing for the recording of results, the stethoscope facilitates the early detection and management of cardiovascular diseases. In addition to its diagnostic tools, HD Medical also offers patient diagnosis and treatment services, contributing to improved outcomes in cardiac health.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

ZKR Ortho is focused on developing innovative medical devices and procedures to address chronic knee pain associated with Condromalacia Patellae, a condition characterized by the degeneration of cartilage in the knee cap. This condition affects millions, often leading to prolonged suffering and delayed medical intervention due to the traditional reliance on major surgery. ZKR's approach offers a minimally invasive solution that aims to relieve pain, restore mobility, and potentially prevent the need for knee replacement. The company has created a clinical-stage orthopedic implant procedure that unloads the patellofemoral joint by elevating the patella tendon, promoting realignment towards healthier cartilage. Founded by Dr. Jeffrey Halbrecht, a noted figure in arthroscopic surgery, ZKR holds multiple patents and is currently seeking funding to advance product trials.

Sepsis Scout is a developer of a wearable patch aimed at predicting the onset of sepsis in high-risk patients in a home care setting. The device utilizes proprietary deep learning technology to enhance the accuracy of sepsis predictions compared to current standards of care. By enabling patients to monitor their health more effectively, Sepsis Scout's solution helps manage chronic illnesses and reduces the need for hospital visits, alleviating the fear and uncertainty associated with serious health conditions.

Conavi Medical specializes in advanced imaging technology for guiding minimally invasive cardiovascular procedures. The company has developed a catheter-based ultrasound system that generates both 2-D and 3-D images of cardiac anatomy around the catheter's tip. This innovative technology aids medical professionals in performing complex procedures, such as ablations, by providing detailed visualization of specific areas within the heart. By enhancing the precision and effectiveness of these interventions, Conavi Medical plays a crucial role in improving patient outcomes in cardiovascular care.

ODS Medical Inc. is a Montreal-based medical device company founded in 2015, specializing in the design and manufacture of innovative diagnostic tools for cancer detection. The company's flagship product is a Raman spectroscopy system that enables real-time detection of tissue abnormalities across various clinical settings. By combining advanced optical probes with sophisticated software powered by machine learning algorithms, ODS Medical aims to enhance physicians' decision-making capabilities, providing them with tools that offer high sensitivity, specificity, and accuracy. Through its commitment to developing groundbreaking medical technology, ODS Medical seeks to improve patient outcomes and support healthcare professionals in their diagnostic processes.

Darmiyan, Inc. is a company that specializes in the development of diagnostic software aimed at the early detection and monitoring of Alzheimer's disease and other neurodegenerative disorders. Based in San Francisco and founded in 2014, the company offers BrainSee, a Software as a Service platform that utilizes non-invasive brain MRI scans to produce detailed brain maps. This innovative tool quantifies neurodegeneration in individual brain voxels and generates a summary score reflecting brain health and the risk of cognitive decline. BrainSee operates using proprietary technology, referred to as The Virtual Microscope, which provides insights into brain cell distortion before clinical symptoms manifest. The algorithm has undergone successful third-party validation in the US and Canada, demonstrating its accuracy in predicting mild cognitive impairment. By leveraging advanced medical imaging and artificial intelligence, Darmiyan aims to enhance early diagnosis and intervention for patients with neurodegenerative diseases.

Deton is dedicated to advancing the understanding and treatment of lung diseases through its innovative diagnostics technology. The company specializes in obtaining samples from the lower respiratory tract, focusing on the detection of lower respiratory tract infections. By utilizing a method known as Aerosol Biopsy, Deton provides comprehensive and timely lung health information. This technology not only aids in diagnosing infections but also preserves bacterial elements for further study, allowing researchers to analyze the growth of fungal and bacterial microbes over time. Through these efforts, Deton facilitates improved diagnosis, detection, and treatment recommendations for various lung disorders.

Impleo Medical focuses on developing minimally invasive medical devices, specifically an outpatient injection therapy platform aimed at treating gastroesophageal reflux disease (GERD). This innovative therapy involves a one-time outpatient procedure performed under sedation, delivering lasting relief from acid reflux symptoms. By providing an alternative to both long-term medication and invasive surgical options, Impleo Medical's treatment addresses a significant gap in GERD management, allowing physicians to effectively prevent the flow of gastric acid into the esophagus.

CU-BX is a health analytics platform focused on enhancing driver safety and in-cabin comfort through advanced monitoring solutions. The company specializes in high-accuracy measurements of critical driver health parameters, including fatigue, stress, and overall comfort levels. Utilizing patented technology, CU-BX's systems deliver precise data regardless of varying road and lighting conditions and are unaffected by clothing or accessories. The platform supports various automotive players, including original equipment manufacturers and component suppliers, by providing driver monitoring systems and aftermarket solutions. CU-BX augments traditional dashcam data with advanced sensors capable of detecting vital signs such as heart rate and respiratory rate, facilitating improved fleet management and safer driving experiences.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Medable, Inc. is a technology company that operates a medical-grade Platform-as-a-Service, designed to facilitate the development of compliant applications and services for the healthcare sector. The platform enables healthcare professionals, hospitals, and medical device manufacturers to create mobile and web applications that support clinical trials while adhering to health privacy regulations. Medable's offerings include solutions for telemedicine, allowing for HIPAA-compliant video consultations and capturing clinical trial outcomes remotely. The platform enhances the efficiency of clinical trials by streamlining design, recruitment, retention, and data quality, thereby improving patient access, experience, and outcomes. Founded in 2015 and headquartered in Palo Alto, California, Medable's solutions are utilized by leading biopharmaceutical companies and clinical research organizations across more than 30 countries and in 26 languages.

PhotoniCare, Inc. is a medical device company based in Champaign, Illinois, founded in 2013. The company specializes in developing innovative diagnostic tools for middle ear infections, notably the TOMi Scope. This handheld device employs advanced light-based technology, specifically near-infrared light waves, to create 3D images of the middle ear by seeing through the eardrum. This capability allows physicians to visualize the middle ear directly and safely, enabling them to assess its condition quickly and accurately. By determining the contents of the middle ear, clinicians can make informed decisions regarding the need for antibiotics or surgical interventions. PhotoniCare's technology not only addresses otology but also presents potential for growth in other medical fields.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Otricath is a company focused on advancing cancer treatment through its innovative closed-loop catheter system specifically designed for liver cancer therapy. This technology allows for the precise delivery of anticancer agents directly to solid tumors, enhancing the efficacy of treatment while minimizing systemic toxicity. The three-part catheter system enables healthcare professionals to administer chemotherapy in a controlled and safe manner, preventing the circulation of toxic agents throughout the patient's body. By prioritizing safety and predictability in therapy delivery, Otricath aims to improve therapeutic outcomes for patients undergoing treatment for liver cancer.

2Morrow, Inc. is a digital health company based in Kirkland, Washington, that specializes in evidence-based behavioral change programs and applications. Founded in 2012, the company offers several products, including SmartQuit, a smoking cessation program utilizing acceptance commitment therapy; My Pocket Coach, a platform designed to help individuals set and achieve personal goals while forming or breaking habits; and Healthy Habits, which focuses on promoting positive behavior change. 2Morrow's programs are distributed through employers, states, wellness initiatives, and health plans, and they emphasize an evidence-based approach to health and wellness. With a commitment to addressing mental, emotional, and behavioral challenges, 2Morrow aims to support individuals in overcoming unhelpful thoughts and urges while pursuing their goals. The company also has ongoing developments in behavioral health and chronic condition management.

OncoTab, Inc. is a North Carolina-based startup co-founded by Dr. Pinku Mukherjee, a Mayo Clinic alumna, with the aim of enhancing cancer care through innovative diagnostic solutions. The company has developed the Agkura™ Personal Score, a non-invasive blood test designed to supplement mammography for women with dense breast tissue, who are at a higher risk of undetected breast cancer. Traditional mammograms can miss up to 50% of cancers in women with high breast tissue density, often leading to late-stage diagnoses. The Agkura™ test provides a continuous score that reflects changes from benign conditions through various stages of breast cancer, allowing patients to monitor their health bi-annually alongside annual mammograms. An increasing score can prompt further imaging, facilitating earlier detection and improving patient outcomes. OncoTab's commitment to addressing unmet diagnostic needs positions it as a key player in the field of cancer diagnostics.

Enspectra Health, based in Mountain View, California, specializes in developing advanced imaging systems for medical applications. The company has created the first hand-held multiphoton imager for human use, enabling real-time imaging of live cellular anatomy beneath the skin. Its innovative device combines reflectance confocal and multiphoton laser scanning microscopy to produce multispectral images that reveal details not visible to the naked eye. This technology aids researchers and dermatologists in examining the structure and function of various tissues, including muscle, tendon, cartilage, and skin, thereby enhancing the diagnosis and treatment of skin conditions, particularly skin cancers. Enspectra Health aims to simplify the evaluation process for physicians and improve patient outcomes through its cutting-edge imaging solutions.

Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, established in 2015. It offers a health data management platform that enables individuals to securely store, manage, and share their health information. The platform empowers patients to take control of their medical records and chronic illness management while facilitating better communication and support between healthcare providers and patients. By integrating a blockchain-enabled network, Patientory streamlines access to health data, enhances care coordination, and provides insights into health outcomes. This approach aims to democratize health data ownership, reduce healthcare costs, and improve overall patient engagement and health management.

Access Vascular, Inc., founded in 2015 and based in Bedford, Massachusetts, specializes in the development of venous access devices that utilize innovative hydrogel materials to prevent thrombosis, infections, and other complications associated with intravenous therapy. The company’s portfolio includes a range of products such as peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. Access Vascular's technology aims to enhance clinical outcomes while reducing healthcare costs by minimizing the risk of blood clots and associated complications. Their flagship product, the HydroPICC, is designed to outperform existing technologies, potentially leading to shorter hospital stays and improved patient experiences. By addressing common challenges in venous access, Access Vascular seeks to improve the effectiveness and safety of intravenous treatments.

NovaGray is focused on creating a new generation of companion diagnostic tests designed to enhance radiation therapy planning. The company develops biomarker-based tests that evaluate patients' sensitivity to radiotherapy through a single blood sample. This approach allows healthcare practitioners to tailor treatment doses and session sequences based on individual patient profiles. By personalizing standard treatments according to patients' specific sensitivities, NovaGray aims to improve clinical outcomes while also reducing both complication and overall treatment costs.

VADovations, Inc. is an Oklahoma City-based company specializing in the design and manufacture of advanced healthcare equipment, particularly focusing on miniaturized ventricular assist devices (VADs) for patients with end-stage heart failure. Founded in 2009, VADovations is developing a smaller and lighter mechanical blood pump that allows for less invasive surgical implantation, significantly reducing hospitalization times from three weeks to four days. The device is designed for percutaneous delivery and endovascular deployment, minimizing the risk of adverse events such as stroke, bleeding, thrombosis, and infection. By addressing the limitations of existing blood pumps, VADovations aims to enhance the capabilities of cardiothoracic surgeons and interventional cardiologists in providing circulatory support for patients in critical need.

Abreos Biosciences, Inc. specializes in the development of lateral flow assays aimed at measuring the activity of biologics, including high-value biologic drugs. The company offers a range of products, such as Veritope, a peptide-based detection reagent used in various applications, including counterfeit detection and dosing guidance for monoclonal antibody therapies. Its C3-LFA lateral flow assay platform is designed for authenticating biologics like BOTOX and conducting endotoxin testing across multiple sectors, including pharmaceuticals and food safety. Additionally, Abreos provides the MudPAQ sensor platform, which facilitates multiplexed protein detection and quantitation, playing a crucial role in proteomic studies related to cancer cells and biomarkers. Founded in 2013 and headquartered in San Diego, California, Abreos Biosciences also operates a laboratory in San Diego and an office in Marseille, France, focusing on enhancing quality assurance, pharmacokinetic monitoring, and prevention of counterfeit drugs in various settings.

Nanowear, Inc. specializes in the development of textile-based nanosensor technology that facilitates wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, the company offers products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, which focuses on the monitoring and management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, which is transmitted to a web-based portal accessible by healthcare professionals via a mobile application. Nanowear's technology serves various sectors, including cardiac and neurological health, industrial safety, government, sports medicine, and performance diagnostics, providing accurate and continuous diagnostic data in a cost-effective and unobtrusive manner. The company also maintains a research and development facility in University Park, Pennsylvania.

Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.

PneuMotion specializes in respiratory monitoring equipment aimed at detecting opioid-induced ventilation impairment. The company offers a solution that provides continuous monitoring of respiratory rates and the detection of obstructive apnea. Its technology is designed to seamlessly integrate into existing hospital networks, facilitating mobile respiratory monitoring and electronic health record (EHR) data collection. By employing ultra-low cost sensor technology, PneuMotion delivers a cost-effective approach to enhancing patient safety, particularly in the context of opioid use.

VerteCore is a developer of an innovative orthopedic medical device aimed at relieving lower back pain. The company has created the VerteCore Lift, a patent-pending system that offers a non-surgical approach to spinal decompression. This device targets various sources of back pain, including compressed or bulging discs, sciatica, and functional scoliosis, using a dual support harness and a unique ratcheting mechanism for ease of use. By providing a convenient and mobile solution, VerteCore enables active individuals to find rapid relief from spinal discomfort without the need for hospitalization, medication, or surgical intervention.

AVA Health Technologies is building a disruptive software platform that addresses challenges in pediatric care for children with acute, chronic, and rare conditions Our vision is to fill the gap in funding and focus in dedicated pediatric research and to provide a collaborative ecosystem for care that can facilitate discovery of new cures.

IntuiTap Medical, established in 2016 and based in Houston, Texas, specializes in manufacturing innovative medical devices. Its flagship product is a handheld device designed to enhance the precision and efficiency of spinal punctures, such as lumbar punctures, spinal anesthesia, and epidurals. This device, the first of its kind, integrates imaging technology with needle guidance and analytics, aiming to eliminate the guesswork, frustration, and pain traditionally associated with these procedures. By improving accuracy and efficiency, IntuiTap's solution aims to reduce procedural costs and instill confidence in both clinicians and patients.

Adient Medical Inc. is a company specializing in the development and delivery of implantable and absorbable medical devices, primarily focused on preventing pulmonary embolisms. Founded in 2012 and headquartered in Pearland, Texas, Adient Medical aims to create devices that are safe and effective throughout their intended use, and then naturally dissolve without the need for surgical removal. This innovative approach not only enhances patient safety but also reduces the potential for complications and the costs associated with removal procedures. Through its absorbable vascular filter, Adient Medical provides healthcare professionals with a safer alternative for managing the risk of pulmonary embolism in patients.

PreDxion Bio is an early-stage healthcare company revolutionizing testing and treatment through low-cost, user-friendly at-home diagnostics. Enabled by PreDxion’s proprietary multiplexed localized surface plasmon resonance (LSPR) technology, our first product is a rapid, saliva-based test for COVID-19, flu, pneumonia, common cold, and other respiratory diseases.

Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

SilverCloud Health, established in 2011, is a digital health company that develops and provides online therapeutic solutions via tailored clinical programs. Headquartered in Boston, Massachusetts, with offices in Dublin, Ireland, and London, UK, the company's SilverCloud platform offers evidence-based, supported digital therapies to various healthcare sectors. It aims to increase client/patient engagement and reduce program dropout rates, as demonstrated by a three-fold improvement in these metrics compared to leading online therapeutic products.

WestFace Medical is a medical device company focused on enhancing vascular access procedures through innovative imaging technology. Their flagship product, SingleStick™, features a patented imaging adapter that employs optical coherence tomography (OCT) to provide real-time visualization of needle trajectories during vascular access. The system consists of a disposable handheld imaging adapter that attaches to any hollow bore needle and an OCT image processor, which displays the captured images. This technology allows clinicians to visualize anatomical markers in real-time, thereby improving clinical outcomes and patient satisfaction while potentially reducing costs associated with vascular access procedures. By offering a solution that facilitates traditional techniques with advanced imaging capabilities, WestFace Medical aims to redefine the standard of care in this critical area of healthcare.

Tueo Health specializes in asthma management through the development of an innovative monitoring system aimed at improving control for children with asthma. The company offers a solution that combines accurate, objective indicators of asthma control with valuable clinical insights tailored to the needs of patients and their families. Utilizing a contactless sensor, the application enables users to monitor and manage asthma treatment progress effectively. This approach not only enhances understanding of asthma conditions but also supports families in achieving optimal health outcomes.

COR helps you implement globally-proven healthy lifestyle practices, then shows you a totally new type of data about how your body responds. Optimize your lifestyle and discover the impact of different daily customs with precise, science-based self-knowledge.

Adient Medical Inc. is a company specializing in the development and delivery of implantable and absorbable medical devices, primarily focused on preventing pulmonary embolisms. Founded in 2012 and headquartered in Pearland, Texas, Adient Medical aims to create devices that are safe and effective throughout their intended use, and then naturally dissolve without the need for surgical removal. This innovative approach not only enhances patient safety but also reduces the potential for complications and the costs associated with removal procedures. Through its absorbable vascular filter, Adient Medical provides healthcare professionals with a safer alternative for managing the risk of pulmonary embolism in patients.

Disease Diagnostic Group (DDG) is a medical device company focused on creating rapid, accurate, and affordable diagnostic tests for diseases. The company has developed a handheld diagnostic device specifically designed for the detection of malaria. This device utilizes magneto-optical technology to identify magnetic nanoparticles produced by the malaria parasite in a single drop of blood. By employing magnets and simple optical methods, the device can detect even minimal quantities of the malaria parasite, providing medical professionals with an effective tool for diagnosis.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

CytoChip Inc. specializes in the design and manufacture of in vitro diagnostic devices, focusing on point-of-care testing solutions. Founded in 2014 and headquartered in Irvine, California, the company has developed the CHIPNOW SYSTEM, which facilitates various diagnostic tests, including complete blood counts and assessments of liver and kidney functions, using a microfluidic design. One of its flagship products, CitoCBC®, allows for rapid, lab-quality complete blood count results from just a single drop of blood, making it suitable for use in physician offices, pharmacy clinics, and even home care settings. With a commitment to enhancing accessibility to reliable diagnostics, CytoChip collaborates with prominent hospitals to support clinical validation and innovation in testing methods. The company operates a research and development center in California, complemented by an engineering and manufacturing facility in Suzhou, China, positioning itself at the forefront of advancements in point-of-care diagnostic technology.

Adult Medical Predictive Devices, Diagnostics and Displays, Inc. (AMP3D) has created a predictive healthcare analytics platform that interprets extensive health data to facilitate early intervention in critical medical situations. The platform identifies potentially life-threatening events such as respiratory de-compensation, hemorrhage, and severe sepsis in real-time, allowing healthcare providers to respond proactively. By employing patented algorithms to analyze physiological monitoring and electronic health record data, AMP3D aims to improve patient outcomes while also reducing costs associated with prolonged hospital stays and emergency interventions. The company intends to market its services on a value-based pricing model, emphasizing demonstrable return on investment linked to quality measures that affect reimbursement. With the potential for significant cost savings—such as an estimated $600,000 annually from a 20% reduction in emergency intubations in a single ICU—the addressable market for AMP3D's solutions in the inpatient sector is considerable, amounting to billions of dollars.